Corbus plans CRB-913 Phase 1b obesity trial data presentation at Obesity Week 2026
CRBP•Corbus Pharmaceuticals plans to present Phase 1b CANYON-1 study data on its oral obesity drug candidate CRB-913 at Obesity Week on November 15, 2026, in National Harbor, Maryland.
1. Planned presentation
Corbus Pharmaceuticals will present CANYON-1 Phase 1b data on CRB-913 at Obesity Week on November 15, 2026, in National Harbor, Maryland. The presentation will cover the candidate’s efficacy, safety and tolerability.
